Head and neck and lung cancer
Approximately 5% of all cancers develop in the mucosa of the head and neck area (Boyle et al., 1990) . A substantial number of these patients present at a moment that curative treatment is possible, due to the fact that many head and neck cancers cause complaints in an early stage. The prognosis of TINO and T2NO glottic laryngeal cancer, for instance, is in the order of 90 and 70% 5 year survival respectively.
It is very likely that the pathogenesis of head and neck cancer is multifactorial. Both tobacco and alcohol are important risk factors in oral, oropharyngeal, hypopharyngeal and laryngeal cancer (Wynder et al., 1956 (Wynder et al., , 1976 Williams & Horn, 1977; Tuyns, 1979; Rothman et al., 1980) . In addition, it is very likely that an individual genetic susceptibility (de Vries et al., 1987a (de Vries et al., , 1987b Schantz & Hsu, 1989; Spitz et al., 1989; Schantz et al., 1990 ) is important if only because so many individuals have been and are being exposed to tobacco and alcohol, whereas only relatively few actually develop cancer in the upper air-and food passages. Patients with head and neck cancers are prone to develop multiple primary cancers (see further), probably because the mucosa of the upper air and food passages is being exposed to the same carcinogens.
The situation in lung cancer patients is different from that of head and neck cancer patients. Lung cancer is the leading cause of cancer deaths in men and the second leading cause of cancer deaths in women, after cancer of the breast. The major factor in the development of lung cancer is the inhalation of tobacco smoke, by susceptible hosts. In contrast to head and neck cancer patients, most lung cancer patients already have a poor prognosis at the time of diagnosis. The 5 year survival rate for all stages of lung cancer has been about 9% for the last 20 years. This small subpopulation of patients that will be cured from their lung cancer are unfortunately prone to develop second primary cancers as well.
Multiple primary tumours occurs in 10-30% of all patients with head and neck cancer and in 10% of patients with, lung cancer (Vrabec, 1979; Gluckman & Crissman, 1983; Tepperman & Fitzpatrick, 1981; Gluckman, 1983; Wagenfeld et al., 1981; Hordijk & de Jong, 1983; , and many others). The great majority of these second primary cancers occur metachronously in the respiratory tract and upper digestive tract.
These second primary tumours usually carry a bad prognosis because they often occur either at notoriously bad sites, like (again in) the lung or esophagus, or within previously *Euroscan Steering treated areas within the head and neck, defying curative treatment. Improvements in local/regional control rates in head and neck cancer patients have not resulted in a proportional increase in survival rates in these patients. The reason for this is that as fewer patients die from uncontrolled disease in the head and neck, more patients are exposed to the risk of second primary tumours (and distant metastases) (Goepfert, 1984 (Bichler & Daxenbichler, 1982; Fex et al., 1986; Friedman et al., 1986 ).
We recently compared serum levels of vitamin A, vitamin E and beta-carotene in patients with head and neck cancer with and without second primary tumours (SPT's) and it was found that in 24 head and neck cancer patients with SPT's the serum levels of vitamin A were lower than in 71 patients with single head and neck cancers.
It was felt that safe drugs were needed in an experimental, large scale study as EUROSCAN was meant to be. Vitamin A has proven to be a relatively safe and non-toxic drug, even when given in high doses and for a long period (Silverman et al., 1963; Bendich et al., 1989) . Retinol Palmitate in an emulsified form has optimal features with regard to intestinal absorbtion, availability from the tissue, with limited liver toxicity. It has been used for many years for skin diseases with acceptable side effects. Based on experience in skin diseases such as psoriasis, ichtyosis and skin cancer, the dose of 300,000 IU daily yields justifiable side effects with comparable response rates as in higher doses.
N-Acetylcysteine N-Acetylcystein (NAC) has attracted attention as a possible chemopreventive agent (van ZandwiUk, 1991) . NAC is a precursor of extracellular and intracellular glutathione (GSH) (de Flora et al., 1985; Cotgreave et al., 1986) and it is widely used in the treatment of patients with chronic bronchitis and emphysema. It has become popular for its potent anti-oxidant/de-toxificant properties. NAC is for instance effective treatment for preventing fatal oxidative liver damage in paracetamol poisoning (Prescott et al., 1979) . NAC has also been shown to give local protection of the urinary tract against iphosphamide and cyclophosphamide induced toxicity (Holoye et al., 1983) . In vitro, NAC is able to inhibit mutagens such as aflatoxin, benzpyrene and cigarette smoke condensate (de Flora, 1984; de Flora et al., 1984 de Flora et al., , 1989 . It prevents chemically induced lung and colon tumours in experimental animals. NAC added before and after the car-cinogen exposure significantly reduced the incidence and multiplicity of lung tumours in mice and of colon tumours in the rat (de Flora et al., 1986; Wilpart et al., 1986) . Evidence has also been provided for the ability of NAC to inhibit DNA adduct formation by either ingested or inhaled carcinogens (de Flora et al., 1991) . The results suggest that it is possible to prevent chemically induced cancers by drugs that raise the levels of physiologically trapping agents such as GSH and that NAC should at least be effective at the initiation stage of carcinogenesis. The significance of antioxidant protection is also underlined by the confirmation of an association between low levels of serum vitamin E and the risk of lung cancer (Byers et al., 1984) . Thus, the restoration of physiological levels of trapping agents in patients who have already had a tumour seems to be an important first step in the prevention of a second tumour. The anticarcinogenic effect of NAC is of particular interest since as mentioned earlier, the drug is safe, without major side effects at the dose of 600 mg/daily and it had been widely used in the treatment of patients with chronic lung disease (Ferrari, 1980) .
Vitamin A and N-acetylcysteine
The combination of the two drugs was chosen for the following reasons. NAC is supposed to be active in early stages of carcinogenesis: before and possibly shortly after the occurrence of DNA damage. Vitamin A is thought to act late during carcinogenesis: in the promotion and progression phases.
NAC as single drug could be active as well as vitamin A, while the combination theoretically covers almost the whole carcinogenic process. No interaction with regard to side effects are expected from the combination.
End points
In total 2,000 patients are planned because the endpoints of EUROSCAN do not only consist of the number of second tumours, local/regional recurrence and distant metastases, but also include long term survival rates.
In the United States of America, much effort at present is devoted to the development of so-called biomarkers as intermediate endpoints in chemoprevention trials (Lippman et al., 1990; Schatzkin et al., 1990) . It is hoped that biomarkers eventually will be identified which are related to epithelial carcinogenesis and which can serve as surrogate endpoint in the conduct of future chemoprevention trials. They would enable us to perform much more chemoprevention studies with less patients, less costs and in less time, than studies that use malignancy as the endpoint.
In No side effects were found for the four treatment arms in 55, 64, 82 and 99 paients, respectively.
Present, but well tolerated side-effects were found in 25, 21, 12 and 0 patients, respectively.
Poorly tolerated side-effects were noted in 14, 9, 2 and 0 patients, respectively. Unbearable side-effects were noted in 14, 9, 2 and 0 patients, respectively. The most common side-effects were dryness, desquamation and itching of the skin, headache and dyspepsia.
It can be concluded that this intermediate analysis of side-effects and toxicity in the first 554 patients of EURO-SCAN has shown that both the single drugs, as well as the combination treatment is well tolerated and that the toxicity is mild and compares favourably with the earlier mentioned intervention scheme as was used by Hong et al. (1990) .
Conclusion
Chemoprevention of second primary tumours in head and neck cancer patients and in lung cancer patients (Pastorino et al., 1988) respectively, is developed from an interesting theoretical model into a realistic adjuvant treatment. The exciting data from the study performed by Hong et al. (1990) need confirmation by larger studies, using drugs less toxic while hopefully equally effective.
The EUROSCAN study is until now running successfully throughout Europe. It is to be hoped that it will give an answer whether this at present still experimental treatment modality will eventually develop into a realistic intervention in cured head and neck cancer and lung cancer patients. When this will be so, it might be that in the future chemopreventive agents will be routinely applied in these extremely high risk patients. At present however, the ideal drug or drug combination, the dose and the duration of administration, have still to be established.
Finally, when chemoprevention of cancer can be reached in high risk groups, other populations at risk, e.g. patients with premalignant lesions, or patients who have been exposed to carcinogenic stimuli as asbestos workers, or even the general population may eventually benefit from intervention measures which currently are being tested in those who are at the highest risk for 'the overshadowing threat for early stage head and neck cancer patients' (Lippman & Hong, 1989) .
